Crosby’s Drugs Inc., Columbus, OH
Is Crosby’s Drugs Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Crosby’s Drugs Inc. hold a Ohio pharmacy license?
State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.
Has Crosby’s Drugs Inc. had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Sep 30, 2021) for Crosby’s Drugs Inc. State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Crosby’s Drugs Inc.
- Location
- Columbus, OH
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Sep 30, 2021
- FDA Data Dashboard inspections
- 1 inspection: 1 OAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 8 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Crosby’s Drugs Inc., a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| Sep 30, 2021 | Form 483 | 483 Issued 09/30/2021 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Crosbys Drugs Inc, Columbus, OH (FEI number 1530045), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 16, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 1530045 | 985395 |
Form 483s FDA has published for this site
- Sep 30, 2021: Form 483 to Crosbys Drugs Inc, published May 26, 2022. fda.gov
- Sep 30, 2016: Form 483 to Crosbys Drugs Inc, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 12, 2016 to Sep 16, 2016: 8 observations
- Firm on the cover
- , 2609 N High St, Columbus, OH 43202- 2555
- FEI number
- 1530045
- Establishment type on the cover
- Producer of St erile Drugs
- FDA district office on the cover
- 6751 St eger Drive Cincinnat i, OH 45237- 3097
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
Specifically,
1) REDACTED (b)(4) papaverine in REDACTED (b)(4) during the production of Tri-Mix on 9/13/16, the employee producing the batch touched the uncovered REDACTED (b)(4) with their bare hands. I
2) There are no smoke studies to demonstrate the effectiveness of the ISO 5 hood used to produce aseptically filled products. 3) No data is available for the process simulation tests (media fills) perfor med to date.
Observation 2
Clothing of personnel engaged in the manufacturing, processing and packing of drug products is not appropriate for the duties they perform.
Specifically,
Gowns and face coverings worn during the production of aseptically filled products in the ISO 5 hood are not sterile and are re-used multiple times throughout the day.
Observation 3
Drug product containers and closures were not clean and sterilized and processed to remove pyrogenic properties to assure that they are suitable for their intended use.
Specifically,
Equipment in direct contact with aseptically filled products, such as REDACTED (b)(4) and REDACTED (b)(4) used to REDACTED (b)(4) papaverine used to produce Tri-Mix, are cleaned with REDACTED (b)(4) and sterile REDACTED (b)(4) and not depyrogenated before use.
Observation 4
The flow of components and in-process materials though the building is not designed to prevent contamination.
Specifically,
Equipment is not disinfected when moved from the ISO 7 clean room into the ISO 5 hood used for producing aseptically filled products.
Observation 5
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
1) Non-viable particulate monitoring and active air sampling for viable particulates in the REDACTED (b)(4) is performed REDACTED (b)(4). 2) Surface sampling of the REDACTED (b)(4) is performed REDACTED (b)(4). 3) Fingertip plating for personnel REDACTED (b)(4) is performed REDACTED (b)(4). 4) No data is available for the environmental and personnel monitoring performed to date, except for the room qualification performed in REDACTED (b)(4).
Observation 6
Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.
Specifically,
There is no data to support that the container closure system for the REDACTED (b)(4) alprosta di l REDACTED (b)(4) used to produce a sep
tically f
illed Tri-Mix is not adversely affected by the st
orage cond itions, REDACTED (b )(4), and REDACTED (b)(4) of the REDACTED (b)(4).
Observation 7
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically,
Aseptically filled sterile drug products, including Tri-Mix, Gentamycin Bladder Irrigation Solution, Quad-Mix, and Acetylcysteine Eye Drops, are not tested for sterility or endotoxin.
Observation 8
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically,
There is no assurance that the finished aseptically filled Tri-Mix, which is produced by REDACTED (b)(4), is stable over the labeled expiry period of 45 days (frozen). I
Linked 483s whose text is not shown
- Sep 30, 2021: FDA document 158593: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.